286 related articles for article (PubMed ID: 26121451)
1. PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Einhorn D; Handelsman Y; Bode BW; Endahl LA; Mersebach H; King AB
Endocr Pract; 2015 Aug; 21(8):917-26. PubMed ID: 26121451
[TBL] [Abstract][Full Text] [Related]
2. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
[TBL] [Abstract][Full Text] [Related]
3. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
[No Abstract] [Full Text] [Related]
4. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
[TBL] [Abstract][Full Text] [Related]
5. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
[TBL] [Abstract][Full Text] [Related]
6. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC
Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235
[TBL] [Abstract][Full Text] [Related]
7. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.
Long T; Lin JT; Lin MH; Wu QL; Lai JM; Li SZ; Zhou ZC; Zeng JY; Huang JS; Zeng CP; Lai YM
Endocr J; 2022 Aug; 69(8):959-969. PubMed ID: 35431280
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
[TBL] [Abstract][Full Text] [Related]
11. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
12. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
[TBL] [Abstract][Full Text] [Related]
13. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.
Onishi Y; Iwamoto Y; Yoo SJ; Clauson P; Tamer SC; Park S
J Diabetes Investig; 2013 Nov; 4(6):605-12. PubMed ID: 24843715
[TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China.
Su W; Li C; Zhang L; Lin Z; Tan J; Xuan J
Diabetes Ther; 2019 Oct; 10(5):1969-1984. PubMed ID: 31482483
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M; Sadeghi M; Barzkar F; Maghsoomi Z; Janani L; Motevalian SA; Loke YK; Ismail-Beigi F; Baradaran HR; Khamseh ME
Front Endocrinol (Lausanne); 2024; 15():1286827. PubMed ID: 38586456
[TBL] [Abstract][Full Text] [Related]
18. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Birkeland KI; Home PD; Wendisch U; Ratner RE; Johansen T; Endahl LA; Lyby K; Jendle JH; Roberts AP; DeVries JH; Meneghini LF
Diabetes Care; 2011 Mar; 34(3):661-5. PubMed ID: 21270174
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials.
Liu W; Yang X; Huang J
Int J Endocrinol; 2018; 2018():8726046. PubMed ID: 29721018
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK.
Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
J Med Econ; 2015 Jan; 18(1):56-68. PubMed ID: 25271378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
